Hannele Tapiovaara

Title: Hannele Tapiovaara: Innovator in Urokinase-type Plasminogen Activator Research

Introduction

Hannele Tapiovaara is a notable inventor based in Helsinki, Finland. She has made significant contributions to the field of medical research, particularly in the area of urokinase-type plasminogen activator receptors. With a total of 2 patents, her work has implications for understanding and treating various medical conditions.

Latest Patents

Hannele's latest patents focus on the inhibition of plasminogen activation. The first patent describes a method to prevent the binding of a receptor binding form of urokinase-type plasminogen activator to its receptor in mammals. This inhibition prevents the conversion of plasminogen into plasmin, which is crucial for various physiological processes. The second patent provides DNA fragments that encode for soluble, active fragments of the urokinase-type plasminogen activator receptor, further advancing the understanding of this important biological mechanism.

Career Highlights

Hannele Tapiovaara is associated with Cancerforskningsfondet Af 1989, where she has been able to apply her research in a practical setting. Her work has been instrumental in advancing the field of cancer research, particularly in understanding the mechanisms of tumor progression and metastasis.

Collaborations

Throughout her career, Hannele has collaborated with esteemed colleagues, including Francesco Blasi and Ann Louring Roldan. These collaborations have enriched her research and contributed to the development of innovative solutions in her field.

Conclusion

Hannele Tapiovaara's contributions to medical research, particularly in the area of urokinase-type plasminogen activator receptors, highlight her role as an influential inventor. Her patents and collaborations continue to pave the way for advancements in cancer research and treatment.